N
38.27
0.56 (1.49%)
| Penutupan Terdahulu | 37.71 |
| Buka | 37.65 |
| Jumlah Dagangan | 1,437,380 |
| Purata Dagangan (3B) | 1,114,364 |
| Modal Pasaran | 4,339,465,728 |
| Harga / Jualan (P/S) | 123.21 |
| Harga / Buku (P/B) | 5.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -2,314.47% |
| EPS Cair (TTM) | -1.84 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 112.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 19.98 |
| Aliran Tunai Operasi (OCF TTM) | -140.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -99.00 M |
| Pulangan Atas Aset (ROA TTM) | -18.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | NewAmsterdam Pharma Company N.V | Menaik | Menurun |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.39% |
| % Dimiliki oleh Institusi | 111.32% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (HC Wainwright & Co., 35.88%) | Beli |
| Median | 46.00 (20.20%) | |
| Rendah | 37.00 (Goldman Sachs, -3.32%) | Pegang |
| Purata | 45.80 (19.68%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 37.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 02 Dec 2025 | 37.00 (-3.32%) | Pegang | 38.33 |
| RBC Capital | 06 Nov 2025 | 44.00 (14.97%) | Beli | 37.05 |
| Needham | 05 Nov 2025 | 46.00 (20.20%) | Beli | 38.13 |
| HC Wainwright & Co. | 20 Oct 2025 | 52.00 (35.88%) | Beli | 37.66 |
| Citigroup | 17 Oct 2025 | 50.00 (30.65%) | Beli | 36.40 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December |
| 07 Nov 2025 | Pengumuman | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Nov 2025 | Pengumuman | NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results |
| 30 Oct 2025 | Pengumuman | NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November |
| 14 Oct 2025 | Pengumuman | Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation |
| 24 Sep 2025 | Pengumuman | NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |